Phacilitate Leaders World

Conference speakers

Loading
Adam Kennedy

Adam Kennedy

Vice President, Morunda

Adam first came to Japan in 2002 while working alongside Philip Carrigan at his first company, and he has been working in search ever since. Adam is especially focused on senior-level positions in the pharmaceuticals and biotechnology sectors. For proof that Adam is one of Japan’s top recruiters, just ask the life science leaders who regularly seek him out for his bottomless knowledge of the industry and his commonsense consulting advice. Although Adam focuses on director-level positions and above, he also takes a personal interest in rare diseases, firms servicing pharma and device manufacturers, and smaller Asian operations that are just getting started. Originally trained in finance, Adam has many financial and operational management roles under his belt in the UK’s National Health Service, as well as with a boutique consulting firm.

Sessions
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK